BGJ398 (Infigratinib)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BGJ398 (Infigratinib), covering 2024-05-08 to 2024-05-08. Get the full timeline:
Most recent: Clinical Trial Update: Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations [Phase 3]